周教授：CameL-sq是一项对比卡瑞利珠单抗联合化疗与单纯化疗治疗局部晚期或转移性鳞状NSCLC的III期临床试验。结果显示，CameL-sq方案的5年总生存（OS）率达27.8%，5年无进展生存（PFS）率为18.2%。这表明超1/4患者实现“临床治愈”（生存突破5年），18.2%的患者疾病控制超过5年，这是非常不错的结果。CameL-sq方案的价值不仅体现在中位OS延长数月（27.4个月vs.15.5个月），其真正的临床意义在于显著提高了患者的长期生存获益。

 

在晚期肺癌研究中，现今应更关注长期生存结局——特别是3年、5年等关键时间节点的OS率数据。我认为未来的临床试验应将长期生存率（如5年生存率）设为主要终点或关键次要终点。临床应使用那些能带来良好长期生存获益的治疗方案。

 

Ruffini教授：晚期肺癌患者实现五年生存，这在几年前被视为天方夜谭。周教授及其团队值得高度赞誉，这是非凡的成就，这是可以在临床实施的方案。

 

Dr.Zhou:Thank you very much for giving me the opportunity to present our data.In this study，we got a very good 5-year survival rate of 27.8%，and a 5-year PFS rate of 18.2%.Excellent results.These data suggest that about one-quarter of patients could get clinical control for five years，and about 18%of patients can be disease-controlled for more than five years.Not bad data.So therapy does not just improve median overall survival by a couple of months(a couple of months for a lung cancer patient is nothing).Nowadays，we should be counting how many patients survive longer–3-year survival，4-year survival and 5-year survival rate.I do think that long-term survival，such as the 5-year survival rate，should be the primary endpoint or key secondary endpoint in future clinical studies.We need to consider therapies with good long-term survival.That’s my thought.

 

Dr.Ruffini:just a brief comment.Of course，the study was in advanced disease if I understood correctly，but just thinking of 5-year survival in advanced disease，is something absolutely unbelievable.Just a few years ago，it would have been absolutely absurd to talk about 5-year survival in advanced disease.Professor Zhou and his team should be congratulated.This is a fantastic achievement.This is of course something that needs to be implemented.